Case Series
Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease
Table 2
Baseline clinical data for 8 patients with CKD stages 4 to 5 who were on denosumab treatment.
| | Case | Number of denosumab doses | Length of hospital stay | Ward/HDU/Outpatient | Time from dose of denosumab to calcium nadir (weeks) | Time to normal calcium level (weeks) | Calcium dose regime prior to admission | Calcitriol dose regime prior to admission | History of fragility fracture |
| | 1 | 1 | 2 | Ward | 12 | 2 | 1g TDS | 250ng twice weekly | No | | 2 | 1 | 4 | HDU | 4 | 8 | Nil | Nil | Yes | | 3 | 1 | 25 | Ward | 8 | 11 | 1g TDS | 250ng daily | No | | 4 | 3 | 11 | HDU | 8 | 7 | Nil | 250ng alternate daily | Yes | | 5 | 4 | 1 | Outpatient | 9 | 8 | 500mg TDS | 250ng thrice weekly | No | | 6 | 6 | 7 | Ward | 8 | 2 | Nil | 250ng daily | No | | 7 | 1 | 8 | Ward | 2 | 1 | 500mg TDS | 250ng daily | No | | 8 | 1 | 10 | HDU | 2 | 1 | Nil | Nil | No |
|
|
